Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485814 | 0.86 | ALDH1A1 (0.54) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL21001635 | 0.84 | ALDH1A1 (0.52) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL3776760 | 0.82 | KDM4E (0.59) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL25721477 | 0.81 | RAB9A (0.49) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL2086826 | 0.80 | POLB (0.48) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL23653213 | 0.78 | RAB9A (0.66) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL2488317 | 0.77 | NPC1 (0.62) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL16376280 | 0.77 | RAB9A (0.50) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL15223780 | 0.76 | HRH4 (0.41) | ALDH1A1RAB9ASMN1; SMN2NPC1GAA | |
| SCHEMBL8176307 | 0.74 | APP (0.48) | POLBAPPHRH4HRH3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-9890159-B2 | Process for making duocarmycin prodrugs | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-02-13 | — | — | US | disclosed |
| US-20170145006-A1 | PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | ALDH1A1 4468/4885RAB9A 1278/4885SMN1; SMN2 3034/4885 |
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | CD274, CD2, CD22 | ALDH1A1 1535/4885RAB9A 2561/4885SMN1; SMN2 2505/4885 |
| US-20170145006-A1 | PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | UMPS, UNG, DNASE1 | ALDH1A1 3757/4885RAB9A 2044/4885SMN1; SMN2 4096/4885 |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | CD274, PDCD1, H1-3 | ALDH1A1 382/4885RAB9A 1819/4885SMN1; SMN2 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.